Regeneus Ltd. articles
Regeneus is excited to announce it is partnering with the Australian Department of Defence to develop its platform stem cell bioactive secretome technology Sygenus for combat casualty care. As part of the grant, Regeneus will receive $300k in funding to optimise the Sygenus formulation to treat combat casualties, including conducting Sygenus’ first in human study on pain.
Q. What is your background and experience in the regenerative medicine and stem cell space? How did this lead you to Regeneus?
A. I’d always had a love for medical research, however found myself working in the pharmaceutical industry after university prior to joining Regeneus. After 6 years in the pharma industry, I’d decided I needed to get back to a research focused career. The timing was perfect when I saw an opening at Regeneus in 2013. Sinc
After being awarded the MTPConnect REDI Fellowship Grant in August 2020, Postdoctoral Research Fellow from the Kolling Institute and University of Sydney Royal North Shore Hospital, Dr. Cindy Shu is joining Regeneus for a 12-month project focused on readying Progenza™ for Phase II trials in Japan and the U.S.
A Medical Research Future Fund initiative, the grant provides financial support to Australian, international and/or multinational medical technology and pharmaceutical comp
Q. What is your background and experience in the regenerative medicine and stem cell space? How did this lead you to Regeneus?
A. I have always had a passion to play a part in improving people’s health and this passion led me to undertaking a Bachelor’s degree of Medical Science at The University of Technology, Sydney (UTS).
It was actually Regeneus that led me into the stem cell and regenerative medicine space – not the other w
Q. Tell us about your role as a Research Scientist and Project Lead at Regeneus?
A. My role is extremely diverse and has evolved over my time at Regeneus. Initially, I was responsible for optimising our product manufacturing processes, including manufacturing products for our preclinical and clinical trials. For example, I provided the data to support preclinical studies that evaluated Progenza™ for osteoarthritis in rabbits and pain in rats.